Job Description
The Medical Director will assist/lead in clinical development activities for Biogen’s Ophthalmology programs within Biogen's Therapeutics Development Unit (TDU). Activities include direct responsibility for advancing clinical development assets (phase I-III) through clinical study design and execution as well as interpretation and communication of the study data. The individual who assumes this position will interact with multiple levels of management within Biogen, external stakeholders in the medical community as well as with global regulatory authorities.
The position of Medical Director, Clinical Development will focus on Biogen’s ophthalmology pipeline, specifically focused on retinal diseases – both inherited and acquired. The successful candidate will understand critical disease areas of high unmet need requiring potentially transformative intervention. The candidate will have demonstrated an ability to support and/or lead clinical development teams, and flexibility to function successfully in a multidisciplinary team environment. In addition, the Director will be responsible for clinical study design and execution as well as interpretation of data from high priority clinical studies, including those developed through external business partnerships. The individual who assumes this position will interact with multiple levels of management and with functions across Biogen, external stakeholders in the medical community and with global regulatory authorities.
The Medical Director has the following responsibilities:
Provide medical and strategic leadership for multiple programs that integrate the individual’s extensive knowledge in basic and clinical science, disease area specialization, and input from the medical community around the world.
Integrate the scientific rationale, regulatory requirements, product development plan, and commercial goals to build a solid strategic framework for the Clinical Development Plan (CDP).
Establish appropriately aggressive clinical development timelines, incorporating key decision points and Go/No Go criteria for the CDP.
Gain approval from internal governance and advisory committees for CDP and study protocols.
Represent Clinical Development on the cross-functional Product Development and Commercialization (PDC) Team and develop and maintain effective relationships with program counterparts in Commercial, Research, Regulatory, Clinical Operations and Statistics.
Contribute to the development of strategic initiatives, specific Business Development activities and various organizational initiatives in Clinical Development.
As appropriate, may serve as R&D Project Leader (RDPL) for specific projects
#LI-NM1
Qualifications
The ideal candidate will have the following mix of professional and personal characteristics:
MD and/or PhD degree required; subspecialty training in Ophthalmology is a plus but not required.
Three (3) to seven (7) years of experience in clinical research with a proven record of achievement on independent research projects. Industry experience is required for the Medical Director title with a preference for ophthalmology, orphan or rare genetic disease experience.
Demonstrated leadership and team building skills as well as the ability to perform effectively in a multi-disciplinary, highly matrixed environment.
Excellent communication skills (oral and written) and excellent organizational skills.
Capacity and willingness to work effectively across disease areas as needed.
The ability to lead directly and by influence, including strong problem solving, conflict resolution, and analytical skills.
Must have the ability to travel for site visits, scientific meetings and other business needs.
Cambridge, MA
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.
Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.
The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.